ly4170156
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started May 6, 2024 (NCT06400472)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 3
- Neoplasm Metastasis · Phase 3
- Ovarian Neoplasms · Phase 3
- Pancreatic Neoplasms · Phase 1
- Peritoneal Neoplasms · Phase 3
- Triple Negative Breast Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Folate receptor alphaINHIBITOR
FOLR1 inhibitor
Chemistry & pharmacology
- Payload
- auristatin
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07213804 | Phase 3 | Oct 22, 2025 | Eli Lilly, European Network for Gynaecological Oncological Trial, GOG Foundation, Inc. |
| NCT06400472 | Phase 1 | May 6, 2024 | Eli Lilly |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 2 | 2 | 2 | 2024 |
| European Network for Gynaecological Oncological Trial | Academic/Hospital | 1 | 0 | 1 | 2025 |
| GOG Foundation, Inc. | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1